运动时双水平无创通气减少重度至极重度COPD患者的动态肺过度充气并改善 cycling 耐力时间
该随机交叉试验纳入19例重度至极重度COPD患者(FEV1 1.02±0.24 L,占预计值39%±6%),比较无NIV、标准化EPAP(5 cm H2O)NIV和个体化滴定EPAP的NIV三种条件下恒定功率 cycling 耐力试验。与无NIV相比,两种NIV均显著提高等时吸气量(S-EPAP均差0.19 L,95%CI 0.10-0.28;T-EPAP均差0.22 L,95%CI 0.13-0.32)并延长耐力时间(S-EPAP均差153 s,95%CI 24-280;T-EPAP均差145 s,95%CI 28-259)。S-EPAP与T-EPAP之间无差异,提示EPAP 5 cm H2O已足够。
要点
- 适用人群:重度至极重度COPD(FEV1占预计值39%±6%)且运动中出现动态肺过度充气者,运动时加用双水平NIV可延长 cycling 耐力时间(S-EPAP均差153 s,95%CI 24-280)。
- 双水平NIV减少运动动态肺过度充气:等时吸气量较无NIV提高0.19 L(S-EPAP,95%CI 0.10-0.28)和0.22 L(T-EPAP,95%CI 0.13-0.32)。
- 标准化EPAP 5 cm H2O与个体化滴定EPAP在改善等时吸气量和耐力时间上无差异,提示EPAP 5 cm H2O已足够。
- 该研究为随机交叉试验,样本量19例,单中心,结果需在更广泛人群和临床场景中验证。
适用人群与场景
- 重度至极重度COPD患者(FEV1 1.02±0.24 L,占预计值39%±6%),静息存在肺过度充气且运动中出现动态肺过度充气证据。
- 研究场景为恒定功率 cycling 耐力试验,非急诊或ICU床旁场景。
诊断标准与关键阈值
- 动态肺过度充气(DH)通过运动时吸气量(IC)下降来评估。
- 原文未提及具体的IC下降阈值或诊断界值。
处置流程与药物剂量
- 第一步:对重度至极重度COPD且运动中出现动态肺过度充气的患者,在运动时考虑使用双水平无创通气(NIV)。
- 第二步:设置EPAP为5 cm H2O(标准化EPAP),原文显示该设置已足以减少动态肺过度充气并延长耐力时间;个体化滴定EPAP未显示额外获益。
- 原文未提及IPAP设置、通气模式参数、给药途径细节或疗程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:随机交叉试验, investigators和participants在NIV干预间设盲;样本量N=19,单中心;人群为重度至极重度COPD(FEV1 1.02±0.24 L,39%±6% predicted)。
- 干预与对照:三种条件随机顺序完成恒定功率 cycling 耐力试验——无NIV、NIV with S-EPAP(5 cm H2O)、NIV with T-EPAP。
- 主要终点:等时IC和运动耐力时间。与无NIV相比,S-EPAP组等时IC均差0.19 L(95%CI 0.10-0.28),耐力时间均差153 s(95%CI 24-280);T-EPAP组等时IC均差0.22 L(95%CI 0.13-0.32),耐力时间均差145 s(95%CI 28-259)。
- S-EPAP与T-EPAP之间无差异。
- 关键次要终点和不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:随机交叉试验(RCT)。
- 证据等级或推荐强度:原文未提及。
- 局限:样本量小(N=19),单中心,交叉设计, investigators和participants在NIV干预间设盲但未提及评估者盲法,结果需外部验证。
对床旁实践的改变
- 对重度至极重度COPD且运动中出现动态肺过度充气的患者,运动时使用双水平NIV(EPAP 5 cm H2O)可减少动态肺过度充气并延长 cycling 耐力时间;个体化滴定EPAP未显示额外获益,可优先使用标准化EPAP 5 cm H2O。
- 适用人群为研究纳入的重度至极重度COPD(FEV1占预计值39%±6%)伴运动动态肺过度充气者;不适用于未纳入人群(如非COPD、轻度COPD、无动态肺过度充气者)。
- 常见陷阱:该研究为小样本单中心交叉试验,结果不能直接外推为急诊或ICU常规推荐;原文未提供IPAP设置、通气模式细节及长期结局。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号:Australian New Zealand Clinical Trials Registry ACTRN12613000804785。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: During exercise, dynamic hyperinflation (DH), measured by a reduction in inspiratory capacity (IC), increases exertional dyspnea and reduces functional capacity in many patients with severe COPD. Although noninvasive ventilation (NIV) during exercise can improve exercise duration, the effect on DH is unclear.
RESEARCH QUESTIONS: In people with COPD, resting hyperinflation, and evidence of DH during exercise, does bilevel NIV during exercise reduce DH and increase endurance time compared with exercise with no NIV, and does NIV with an individually titrated expiratory positive airway pressure (T-EPAP) reduce DH and increase exercise endurance time more than NIV with standardized EPAP (S-EPAP) of 5 cm H2O?
STUDY DESIGN AND METHODS: A randomized crossover trial in which investigators and participants were blinded between NIV interventions was performed. Participants (N = 19; FEV1 of 1.02 ± 0.24 L (39% ± 6% predicted) completed three constant work rate endurance cycle tests in random order-no NIV, NIV with S-EPAP, and NIV with T-EPAP-during exercise. Primary outcomes were isotime IC and exercise endurance time. Outcome measures from each intervention were compared at isotime and at end exercise by using a linear mixed-model analysis.
RESULTS: Compared with no NIV, isotime IC and endurance time were greater with both NIV with S-EPAP (mean difference: 95% CI, 0.19 L [0.10-0.28]; 95% CI, 153 s [24-280], respectively) and T-EPAP (95% CI, 0.22 L [0.13-0.32]; 95% CI, 145 s [28-259], respectively). There was no difference between NIV with S-EPAP and NIV with T-EPAP.
INTERPRETATION: In people with COPD and DH during exercise, NIV during exercise reduced DH and increased cycle endurance time. An S-EPAP of 5 cm H2O was adequate to obtain these benefits.
TRIAL REGISTRY: Australian New Zealand Clinical Trials Registry; No.: ACTRN12613000804785; URL: http://www.anzctr.org.au.
参考来源
- Dennis CJ, Menadue C, Schneeberger T, et al. Bilevel Noninvasive Ventilation During Exercise Reduces Dynamic Hyperinflation and Improves Cycle Endurance Time in Severe to Very Severe COPD. Chest. 2021. PMID: 34224690. doi:10.1016/j.chest.2021.06.050
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。